Moderna, the US vaccine manufacturer, has signed agreements and a land cooperation deal in China to facilitate research, development, and production of mRNA drugs, according to Bloomberg and Reuters.
The company confirmed that drugs produced under this agreement will be exclusively for the Chinese market.
While the spokesperson declined to disclose specific details or the scale of the deal, insiders suggest that Moderna's investment in China could reach approximately US$1 billion (7.24 billion yuan).
Moderna's CEO, Stéphane Bancel, has arrived in Shanghai and is expected to announce the investment project officially.
